Pharmacotherapy Review of Chronic Pediatric Hypertension

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1331-1356

  Meyers, Rachel S ^a,b   Siu, Anita ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; CHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; FELODIPINE; FOSINOPRIL; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISRADIPINE; LABETALOL; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MINOXIDIL; NIFEDIPINE; OLMESARTAN; PRAZOSIN; PROPRANOLOL; RAMIPRIL; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE KIDNEY FAILURE; ANEMIA; ANKLE EDEMA; ANOREXIA; ANTIHYPERTENSIVE THERAPY; ARM FRACTURE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLURRED VISION; BODY WEIGHT; BRADYCARDIA; CHRONIC PEDIATRIC HYPERTENSION; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FACE EDEMA; FATIGUE; FLUID RETENTION; FLUSHING; FOOT EDEMA; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HAND EDEMA; HEART PALPITATION; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMORRHAGIC INFARCTION; HEPATITIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPESTHESIA; HYPOTENSION; INSOMNIA; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY FUNCTION; LEG CRAMP; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MEDLINE; MENOMETRORRHAGIA; MIGRAINE; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; OLIGURIA; PHARYNGITIS; PNEUMONIA; POSTURAL SYMPTOM; POTASSIUM BLOOD LEVEL; PROTEINURIA; PSYCHIATRIC NEGATIVISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SORE THROAT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TOOTH PAIN; TORTICOLLIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; HUMANS; HYPERTENSION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054941990     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.003     Document Type: Review

References (127)

1. Schiel R., Beltschikow W., Kramer G., Stein G. Overweight, obesity, and elevated blood pressure in children and adolescents. Eur J Med Res 2006, 11:97-101.
2. Sorof J.M., Lai D., Turner J., et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 2004, 113(3 Pt 1):475-482.
3. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 2004, 114:555-576.
4. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
5. Flynn J.T., Mitsnefes M., Pierce C., et al. Blood pressure in children with chronic kidney disease. A report from the chronic kidney disease in children study. Hypertension 2008, 52:631-637.
6. Sinaiko A.R., Steinberger J., Moran A., et al. Relation of insulin resistance to blood pressure in childhood. J Hypertens 2002, 20:509-517.
7. Lexi-Comp I. Pediatric Lexi-Drugs Online [database on the Internet]. 2010; Accessed December 13, 2010.
8. Thomson Reuters (Healthcare) Inc. Micromedex Healthcare Series [database on the Internet].
9. Sinaiko A.R., Mirkin B.L., Hendrick D.A., et al. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr 1983, 103:799-805.
10. Mirkin B.L., Newman T.J. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the international collaborative study group. Pediatrics 1985, 75:1091-1100.
11. Sinaiko A.R., Kashtan C.E., Mirkin B.L. Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Hypertens A 1986, 8:829-839.
12. Bouissou F., Meguira B., Rostin M., et al. Long term therapy by captopril in children with renal hypertension. Clin Exp Hypertens A 1986, 8:841-845.
13. O'Dea R.F., Mirkin B.L., Alward C.T., Sinaiko A.R. Treatment of neonatal hypertension with captopril. J Pediatr 1988, 113:403-406.
14. Tack E.D., Perlman J.M. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 1988, 112:805-810.
15. Wells T., Frame V., Soffer B., et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002, 42:870-880.
16. Soffer B., Zhang Z., Miller K., et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hyperten 2003, 16:795-800.
17. Soergel M., Verho M., Wühl E., et al. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr Nephrol 2000, 15:113-118.
18. Wühl E., Mehls O., Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004, 66:768-776. ESCAPE Trial Group.
19. Wühl E., Trivelli A., Picca S., et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009, 361:1639-1650. ESCAPE Trial Group.
20. Sabroe R.A., Black A.K. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997, 136:153-158.
21. Li J.S., Berezny K., Kilaru R., et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?. Hypertension 2004, 44:289-293.
22. Menon S., Berezny K.Y., Kilaru R., et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am Heart J 2006, 152:394-399.
23. Ellis D., Moritz M.L., Vats A., Janosky J.E. Antihypertensive and renoprotective efficacy and safety of losartan. Am J Hypertens 2004, 17:928-935.
24. Shahinfar S., Cano F., Soffer B.A., et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 2005, 18:183-190.
25. Flynn J.T., Meyers K.E., Neto J.P., et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension 2008, 52:222-228.
26. von Vigier R.O., Zberg P.M., Teuffel O., Bianchetti M.G. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. Eur J Pediatr 2000, 159:590-593.
27. Franscini L.M., von Vigier R.O., Pfister R., et al. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney disease. Am J Hypertens 2002, 15:1057-1063.
28. Simonetti G.D., von Vigier R.O., Konrad M., et al. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatr Nephrol 2006, 21:1480-1482.
29. Trachtman H., Hainer J.W., Sugg J., et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008, 10:743-750.
30. Franks A.M., O'Brien C.E., Stowe C.D., et al. Candesartan cilexetil effectively reduces blood pressure in hypertensive children. Ann Pharmacother 2008, 42:1388-1395.
31. Schaefer F., Van de Walle J., Zurowska A., et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 2010, 28:1083-1090.
32. Hazan L., Hernández Rodriguez O.A., Bhorat A.E., et al. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 2010, 55:1323-1330.
33. Olmesartan medoxomil [package insert] 2009, Daiichi Sankyo, Parsippany, NJ.
34. Pfammatter J.P., Clericetti-Affolter C., Truttmann A.C., et al. Amlodipine once-daily in systemic hypertension. Eur J Pediatr 1998, 157:618-621.
35. Khattak S., Rogan J.W., Saunders E.F., et al. Efficacy of amlodipine in pediatric bone marrow transplant patients. Clin Pediatr (Phila) 1998, 37:31-35.
36. Rogan J.W., Lyszkiewicz D.A., Blowey D., et al. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol 2000, 14:1083-1087.
37. Flynn J.T., Smoyer W.E., Bunchman T.E. Treatment of hypertensive children with amlodipine. Am J Hypertens 2000, 13:1061-1066.
38. von Vigier R.O., Franscini L.M., Bianda N.D., et al. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens 2001, 15:387-391.
39. Parker M.L., Robinson R.F., Nahata M.C. Amlodipine therapy in pediatric patients with hypertension. J Am Pharm Assoc 2002, 42:114-117.
40. Flynn J.T., Newburger J.W., Daniels S.R., et al. A randomized placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 2004, 145:353-359.
41. Flynn J.T. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 2005, 20:631-635.
42. Andersen J., Groshong T., Tobias J.D. Preliminary experience with amlodipine in the pediatric population. Am J Ther 2006, 13:198-204.
43. Flynn J.T., Warnick S.J. Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol 2002, 17:748-753.
44. Trachtman H., Frank R., Mahan J.D., et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003, 18:548-553.
45. Moncica I., Oh P.I., ul Qamar I., et al. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Childhood 1995, 73:154-156.
46. Silverstein D.M., Palmer J., Baluarte H.J., et al. Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr Transplant 1999, 3:288-292.
47. Griswold W.R., McNeal R., Mendoza S.A., et al. Propranolol as an antihypertensive agent in children. Arch Dis Childhood 1978, 53:594-596.
48. Falkner B., Lowenthal D.T., Affrime M.B. The pharmacodynamic effectiveness of metoprolol in adolescent hypertension. Pediatric Pharmacology 1982, 2:49-55.
49. Batisky D.L., Sorof J.M., Sugg J., et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 2007, 150:134-139.
50. Sorof J.M., Cargo P., Graepel J., et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 2002, 17:345-350.
51. Sinaiko A.R., Mirkin B.L. Management of severe childhood hypertension with minoxidil: a controlled clinical study. J Pediatr 1977, 91:138-142.
52. Sinaiko A.R., O'Dea R.F., Mirkin B.L. Clinical response of hypertensive children to long-term minoxidil therapy. J Cardiovasc Pharmacol 1980, 2(Suppl 2):S181-S188.
53. Puri H.C., Maltz H.E., Kaiser B.A., Potter D.E. Severe hypertension in children with renal disease: treatment with minoxidil. Am J Kidney Dis 1983, 3:71-75.
54. Strife C.F., Quinlan M., Waldo F.B., et al. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 1986, 78:861-865.
55. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411-1420.
56. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
57. Ruggenenti P., Perna A., Gherardi G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998, 352:1252-1256.
58. White C.T., Macpherson C.F., Hurley R.M., Matsell D.G. Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr Nephrol 2003, 18:1038-1043.
59. Friedman A.L., Chesney R.W. Effect of captopril on the renin-angiotensin system in hypertensive children. J Pediatr 1983, 103:806-810.
60. Sagat T., Sasinka M., Furkova K., et al. Treatment of renal hypertension in children by captopril. Clin Exp Hypertens A 1986, 8:853-857.
61. Callis L., Vila A., Catala J., Gras X. Long-term treatment with captopril in pediatric patients with severe hypertension and chronic renal failure. Clin Exp Hypertens A 1986, 8:847-851.
62. Rosendahl W., Hayduk K. Successful acute and long-term treatment of renin-induced hypertension in two infants with captopril. Eur J Pediatrics 1980, 135:161-164.
63. Oberfield S.E., Rapaport R., Levine L.S., New M.I. Long-term treatment of childhood hypertension with captopril. Pediatr Ann 1982, 11:614-616. 620-621.
64. Hogg R.J., Delucchi A., Sakihara G., et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol 2007, 22:695-701.
65. Raes A., Malfait F., Van Aken S., et al. Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children. J Renin-Angiotensin-Aldosterone System 2007, 8:3-12.
66. Wells T., Rippley R., Hogg R., et al. The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol 2001, 41:1064-1074.
67. Saini S.D., Schoenfeld P., Kaulback K., Dubinsky M.C. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009, 15:e22-e33.
68. Blumer J.L., Daniels S.R., Dreyer W.J., et al. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. J Clin Pharmacol 2003, 43:128-132.
69. Li J.S., Baker-Smith C.M., Smith P.B., et al. Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis. Clin Pharmacol Ther 2008, 84:315-319.
70. Schilder J.L., Van den Anker J.N. Use of enalapril in neonatal hypertension. Acta Paediatrica 1995, 84:1426-1428.
71. Hricik D.E., Browning P.J., Kopelman R., et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. N Engl J Med 1983, 308:373-376.
72. Overlack A. ACE Inhibitor-induced cough and bronchospasm. Drug Safety 1996, 15:72-78.
73. Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992, 117:234-242.
74. Baker-Smith C.M., Benjamin D.K.J., Califf R.M., et al. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 2010, 87:668-671.
75. von Vigier R.O., Mozzettini S., Truttmann A.C., et al. Cough is common in children prescribed converting enzyme inhibitors. Nephron 2000, 84:98.
76. Vleeming W., van Amsterdam J.G., Stricker B.H., de Wildt D.J. ACE inhibitor-induced angioedema. Drug Safety 1998, 18:171-188.
77. Malde B., Regalado J., Greenberger P.A. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007, 98:57-63.
78. Hanssens M., Keirse M.J., Vankelecom F., Van Assche F.A. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstetrics Gynecol 1991, 78:128-135.
79. Ram C.V. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008, 121:656-663.
80. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
81. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
82. Seeman T., Pohl M., Misselwitz J., John U. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with angiotensin-converting enzyme inhibitors. Kidney Blood Pressure Res 2009, 32:440-444.
83. Herder S.D., Weber E., Winkemann A., et al. Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents. Pediatr Nephrol 2010, 25:801-811.
84. Ellis D., Vats A., Moritz M.L., et al. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr 2003, 143:89-97.
85. Blumer J., Batisky D.L., Wells T., et al. Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. J Clin Pharmacol 2009, 49:235-241.
86. Habtemariam B., Sallas W., Sunkara G., et al. Population pharmacokinetics of valsartan in pediatrics. Drug Metab Pharmacokinetics 2009, 24:145-152.
87. Salcedo-Alejos M., Banda-Espinoza F., Rodríguez-Morán M., Guerrero-Romero F. Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial. Nephrology Dialysis Transplant 2005, 20:2120-2125.
88. Sakarcan A., Tenney F., Wilson J.T., et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001, 41:742-749.
89. Muir V.J., Keating G.M. Olmesartan medoxomil in children and adolescents with hypertension. Drugs 2010, 70:2439-2447.
90. Benicar® (olmesartan medoxomil) tablets clinical review. 2010 US Food and Drug Administration, Accessed August 8, 2011. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM201695.pdf.
91. Valsartan [package insert] 2011, Novartis Pharmaceuticals Corp, East Hanover, NJ.
92. Meier C.M., Simonetti G.D., Ghiglia S., et al. Palatability of angiotensin II antagonists among nephropathic children. Br J Clin Pharmacol 2006, 63:628-631.
93. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000, 355:637-645.
94. Pylypchuk G.B. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998, 32:1060-1066.
95. Cicardi M., Zingale L.C., Bergamaschini L., Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004, 164:910-913.
96. Abdi R., Dong V.M., Lee C.J., Ntoso K.A. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 2002, 22:1173-1175.
97. Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Pediatric Drugs 2006, 8:357-373.
98. Tallian K.B., Nahata M.C., Turman M.A., et al. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 1999, 13:304-310.
99. Flynn J.T., Nahata M.C., Mahan J.D.J., Portman R.J. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol 2006, 46:905-916. Path-2 Investigators.
100. Norvasc (amlodipine besylate) tablet [package insert] 2006, Pfizer, Inc, New York, NY.
101. Nahata M.C., Morosco R.S., Hipple T.F. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharmaceutical Assoc 1999, 39:375-377.
102. Lyszkiewicz D.A., Levichek Z., Kozer E., et al. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol 2003, 18:675-678.
103. Strauser L.M., Groshong T., Tobias J.D. Initial experience with isradipine for the treatment of hypertension in children. South Med J 2000, 93:287-293.
104. Blowey D.I., Moncica I., Scolnik D., et al. The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol 1996, 50:147-148.
105. Robinson R.F., Nahata M.C., Batisky D.L., Mahan J.D. Pharmacologic treatment of chronic pediatric hypertension. Pediatric Drugs 2005, 7:27-40.
106. Ishisaka D.Y., Yonan C.D., Housel B.F. Labetalol for treatment of hypertension in a child. Clin Pharmacy 1991, 10:500-501.
107. NCAA Banned Drug List National Collegiate Athletic Association, Accessed October 3, 2010. http://www.ncaa.org/wps/wcm/connect/public/ncaa/student-athlete+experience/ncaa+banned+drugs+list.
108. Tafreshi M.J., Weinacker A.B. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy 1999, 19:974-978.
109. Propranolol (propranolol hydrochloride) tablet [package insert] 2009, Watson Pharma Inc, Corona, Calif.
110. Kallen R.J., Mohler J.H., Lin H.L. Hypoglycemia: a complication of treatment of hypertension with propranolol. Clin Pediatr 1980, 19:567-568.
111. Wargo K.A., Banta W.M. A comprehensive review of the loop diuretics: should furosemide be first line?. Ann Pharmacother 2009, 43:1836-1847.
112. Ernst M.E., Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009, 361:2153-2164.
113. Marrs J.C. Spironolactone management of resistant hypertension. Ann Pharmacother 2010, 44:1762-1769.
114. Aranda J.V., Lambert C., Perez J., et al. Metabolism and renal elimination of furosemide in the newborn infant. J Pediatr 1982, 101:777-781.
115. Peterson R.G., Simmons M.A., Rumack B.H., et al. Pharmacology of furosemide in the premature newborn infant. J Pediatr 1980, 97:139-143.
116. Tuck S., Morselli P., Broquaire M., Vert P. Plasma and urinary kinetics of furosemide in newborn infants. J Pediatr 1983, 103:481-485.
117. Mirochnick M.H., Miceli J.J., Kramer P.A., et al. Furosemide pharmacokinetics in very low birth weight infants. J Pediatr 1988, 112:653-657.
118. Amiloride hydrochloride tablet [package insert] 2009, Par Pharmaceutical, Inc, Spring Valley, NY.
119. Aldactone (spironolactone) tablet, film coated [package insert] 2008, Pfizer, Inc, New York, NY.
120. Sica D.A. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich) 2004, 6:283-287.
121. Kandler M.R., Mah G.T., Tejani A.M., Stabler S.N. Hydralazine for essential hypertension. Cochrane Database Syst Rev 2010, (8). CD004934.
122. Minipress (prazosin hydrochloride) [package insert] 2009, Pfizer, Inc, New York, NY.
123. Catapres (clonidine hydrochloride) tablet [package insert] 2010, Boehringer Ingelheim Pharmaceuticals, Inc, Ingelheim, Germany.
124. Halling S.E., Asling-Monemi K., Herthelius M., et al. Minoxidil therapy in children and young adult patients with renal disease and refractory hypertension: value when multidrug regimens have failed to achieve blood pressure control. J Hum Hypertens 2010, 24:552-554.
125. Benjamin D.K.J., Smith P.B., Jadhav P., et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 2008, 51:834-840.
126. Loniten (minoxidil) tablet [package insert] 2002, Pharmacia & Upjohn Company, New York, NY.
127. Flynn J.T., Daniels S.R. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr 2006, 149:746-754.